Structure Therapeutics Inc. (GPCR) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
GPCR EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
GPCR Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export GPCR earnings history in CSV or JSON format
Free sign-in required to download data
Structure Therapeutics Inc. (GPCR) Earnings Overview
As of May 8, 2026, Structure Therapeutics Inc. (GPCR) reported trailing twelve-month net income of -$170M, reflecting -2.6% year-over-year growth. The company earned $-2.35 per diluted share over the past four quarters.
Looking at the long-term picture, GPCR's historical earnings data spans multiple years. The company achieved its highest annual net income of -$16M in fiscal 2020.
Structure Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CHRS ($168M net income, 398.4% margin), RVMD (-$1.37B net income), KYMR (-$315M net income, -794.4% margin), GPCR has comparable earnings metrics. Compare GPCR vs CHRS →
GPCR Earnings vs Peers
Earnings metrics vs comparable public companies
GPCR Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$141M | -15.2% | -$288M | $-2.40 | - | - |
| 2024 | -$123M | -36.7% | -$158M | $-2.34 | - | - |
| 2023 | -$90M | -74.6% | -$103M | $-2.43 | - | - |
| 2022 | -$51M | -28.3% | -$53M | $-1.44 | - | - |
| 2021 | -$40M | -151.6% | -$38M | $-1.20 | - | - |
| 2020 | -$16M | - | -$16M | $-0.45 | - | - |
See GPCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GPCR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GPCR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGPCR — Frequently Asked Questions
Quick answers to the most common questions about buying GPCR stock.
Is GPCR growing earnings?
GPCR EPS of $-2.35 reflects slowing growth at -2.6%, below the 5-year CAGR of N/A. TTM net income is $-170M. Expansion rate has moderated.
What are GPCR's profit margins?
Structure Therapeutics Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are GPCR's earnings?
GPCR earnings data spans 2020-2025. The current earnings trend is -2.6% YoY. Historical data enables comparison across business cycles.